Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23544829 | 0.84 | FAAH (0.43) | ALDH1A1KDM4EHTTFAAHMEN1 | |
| SCHEMBL15829985 | 0.81 | ALDH1A1 (0.57) | ALDH1A1KDM4EHTTMAPTFAAH | |
| SCHEMBL22516951 | 0.76 | ACHE (0.53) | ALDH1A1KDM4EHTTMAPTMEN1 | |
| SCHEMBL178443 | 0.74 | NCF1 (0.66) | ALDH1A1KDM4EHTTMAPTLMNA | |
| SCHEMBL12447 | 0.73 | BACE1 (0.59) | ALDH1A1KDM4EHTTMAPTMEN1 | |
| SCHEMBL27895731 | 0.73 | ACHE (0.59) | ALDH1A1KDM4EHTTMAPTMEN1 | |
| SCHEMBL10076573 | 0.73 | MC4R (0.65) | ALDH1A1KDM4EHTTMAPTFAAH | |
| SCHEMBL15829984 | 0.73 | ALDH1A1 (0.62) | ALDH1A1KDM4EHTTMAPTFAAH | |
| SCHEMBL31546411 | 0.72 | HRH3 (0.69) | ALDH1A1KDM4EHTTMAPT | |
| SCHEMBL12981 | 0.72 | HRH3 (0.69) | ALDH1A1KDM4EHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | JAK3, JAK1, JAK2 | ALDH1A1 2446/4885KDM4E 1182/4885HTT 4020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.